HCP
DNA icon

Hexagon Capital Partners’s Ginkgo Bioworks DNA Stock Holding History

Hexagon Capital Partners’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-178
Closed -$1.01K – 498
2025
Q1 		$1.01K Buy
178
+153
+612% +$1.56K ﹤0.01% 1546
2024
Q4 		$246 Sell
25
-18
-42% -$154 ﹤0.01% 1751
2024
Q3 		$350 Buy
+43
New +$431 ﹤0.01% 1447

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hexagon Capital Partners's DNA Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 178 shares — an estimated $1.01K sold.

Hexagon Capital Partners first reported a position in DNA in Q3 2024 and held it in 3 quarters. The position peaked at $1.01K in Q1 2025. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 178 Ginkgo Bioworks shares in Q2 2025, an estimated $1.01K.
  • Hexagon Capital Partners first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 3 quarters.
  • Hexagon Capital Partners's Ginkgo Bioworks position peaked at $1.01K in Q1 2025.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.